Solid Biosciences (SLDB) Cash & Equivalents (2017 - 2024)
Historic Cash & Equivalents for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $64.4 million.
- Solid Biosciences' Cash & Equivalents rose 3131.72% to $64.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $64.4 million, marking a year-over-year increase of 3131.72%. This contributed to the annual value of $74.0 million for FY2023, which is 5236.64% down from last year.
- Per Solid Biosciences' latest filing, its Cash & Equivalents stood at $64.4 million for Q3 2024, which was up 3131.72% from $95.9 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Cash & Equivalents ranged from a high of $268.5 million in Q1 2021 and a low of $24.8 million during Q3 2020
- Over the past 5 years, Solid Biosciences' median Cash & Equivalents value was $95.9 million (recorded in 2024), while the average stood at $106.1 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 7382.07% in 2020, then skyrocketed by 40481.7% in 2021.
- Quarter analysis of 5 years shows Solid Biosciences' Cash & Equivalents stood at $154.7 million in 2020, then dropped by 23.01% to $119.1 million in 2021, then surged by 30.43% to $155.4 million in 2022, then crashed by 52.37% to $74.0 million in 2023, then dropped by 13.0% to $64.4 million in 2024.
- Its Cash & Equivalents was $64.4 million in Q3 2024, compared to $95.9 million in Q2 2024 and $117.6 million in Q1 2024.